Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation

European Heart Journal, Supplement

Volumn 7, Issue C, 2005, Pages

  Miller, Paul S J ^a   Drummond, Michael F ^b   Langkilde, Lars K ^c   McMurray, John J V ^d   Ögren, Mats ^c  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSITY OF YORK   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

^d WESTERN INFIRMARY   (United Kingdom)

Author keywords

Anticoagulants; Arrhythmia; Health economic analysis; Prevention; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STROKE; THROMBOEMBOLISM; UPPER GASTROINTESTINAL BLEEDING;

EID: 18744373021     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1093/eurheartj/sui019     Document Type: Review

References (111)

1. Chalmers J, Chapman N. Progress in reducing the burden of stroke. Clin Exp Pharmacol Physiol 2001;28:1091-1095.
2. Evers SM, Struijs JN, Ament AJ et al. International comparison of stroke cost studies. Stroke 2004;35:1209-1215.
3. Martinez-Vila E, Irimia P. The cost of stroke. Cerebrovosc Dis 2004;17(Suppl. 1):124-129.
4. American Heart Association. 1998 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 1997.
5. Organisation for Economic Co-operation and Development. Purchasing Power Parities for OECD countries 1980-2004. http://www.oecd.org/LongAbstract/0,2546, en_2649_201185_1876126_1_ 1_1_1,00.html (2 August 2004).
6. Lamassa M, Di Carlo A, Pracucci G et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe. Data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001;32:392-398.
7. Narayan SM, Cain ME, Smith JM. Atrial fibrillation. Lancet 1997;350:943-950.
8. Ryder KM, Benjamin EJ. Epidemiology and significance of atrial fibrillation. Am J Cardiol 1999;84:131R-138R.
9. Morgan S, Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. Br J Gen Pract 2002;52:373-380.
10. Stewart S, Murphy N, Walker A et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart 2004;90:286-292.
11. Steinberg J. Atrial fibrillation: an emerging epidemic? Heart 2004;90:239-240.
12. Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-2375.
13. Hjelmgren J, Berggren F, Andersson F. Health economic guidelines (similarities, differences and some implications. Value Health 2001;4:225-250.
14. Sullivan SD, Lyles A, Luce B et al. AMCP Guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organisations. J Manag Care Pharm 2001;7:272-282.
15. Hart RG, Benavente O, McBride R et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
16. Ansell J, Hirsh J, Poller L et al. The pharmacology and management of vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126 (Suppl. 3):204S-286S.
17. Singer DE, Albers GW, Dalen JE et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):429S-456S.
18. Fuster V, Ryden LE, Asinger RW et al. American College of Cardiology; American Heart Association; European Society of Cardiology; North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J 2001;22:1852-1923.
19. Bungard TJ, Ghali WA, Teo KK et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-46.
20. Buckingham TA, Hatala R. Anticoagulants for atrial fibrillation: why is the treatment rate so low? Clin Cardiol 2002;25:447-454.
21. Drummond MF, O'Brien BJ, Stoddart GL et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 1997.
22. Taylor TN, Davis PH, Torner JC et al. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-1466.
23. Fagan SC, Morgenstern LB, Petitta A et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology 1998;50:883-890.
24. Dewey HM, Thrift AG, Mihalopoulos C et al. Lifetime cost of stroke subtypes in Australia: findings from the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2003;34:2502-2507.
25. Bergman L, van der Meulen JH, Limburg M et al. Costs of medical care after first-ever stroke in The Netherlands. Stroke 1995; 26:1830-1836.
26. Persson U, Silverberg R, Lindgren B et al. Direct costs of stroke for a Swedish population. Int J Technol Assess Health Care 1990; 6:125-137.
27. Terént A, Marké LA, Asplund K et al. Costs of stroke in Sweden: a national perspective. Strate 1994;25:2363-2369.
28. Ghatnekar O, Persson U, Glader EL et al. Cost of stroke in Sweden: an incidence estimate. Int J Technol Assess Health Care 2004; 20:375-380.
29. Lightowlers S, McGuire A. Cost-effectiveness of anticoagulation in non-rheumatic atrial fibrillation in the primary prevention of ischemic stroke. Stroke 1998;29:1827-1832.
30. Caro JJ, Huybrechts KF for the Stroke Economic Analysis Group. Stroke treatment economic model (STEM): predicting long-term costs from functional status. Stroke 1999;30:2574-2579.
31. Carod-Artal FJ, Egido-Navarro JA, Gonzalez-Gutierrez JL et al. Direct cost of cerebrovascular disease during the first year of follow-up. Rev Neurol 1999;29:1353-1355.
32. US Department of Labor, Bureau of Labor Statistics, Consumer Price Indexes: Inflation calculator. http://www.bls.gov/cpi/home.htm (14 April 2004)
33. Lin HJ, Wolf PA, Kelly-Hayes M et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996;27:1760-1764.
34. Jorgensen HS, Nakayama H, Reith J et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27:1765-1769.
35. Appelros P, Nydevik I, Seiger A et al. Predictors of severe stroke. Influence of pre-existing dementia and cardiac disorders. Stroke 2002;33:2357-2362.
36. Appelros P, Nydevik I, Viitanen M. Poor outcome after first-ever stroke. Predictors for death, dependency, and recurrent stroke within the first year. Stroke 2003;34:122-126.
37. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemioiogy 2003;22: 118-123.
38. Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated? Stroke 2005;36:360-366.
39. Claesson L, Gosman-Hedstrom G, Johanesson M, et al. Resource utilization and costs of stroke unit care integrated in a care continuum: a 1-year controlled, prospective, randomized study in elderly patients. The Goteborg 70+ Stroke Study. Stroke 2000;31: 2569-2577.
40. Youman P, Wilson K, Harraf F et al. The economic burden of stroke in the United Kingdom. Pharmacoeconomics 2003;21:43-50.
41. Thomson R, Parkin D, Eccles M et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet 2000;355:956-962.
42. Gage BF, Cardinalli AB, Albers GW et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA 1995;274:1839-1845.
43. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998;29:1083-1091.
44. Caro JJ, O'Brien JA, Klittich W et al. The economic impact of warfarin prophylaxis in nonvalvular atrial fibrillation. Dis Manag Clin Outcomes 1997;1:54-60.
45. Gold MR, Siegel JE, Russell LB et al. Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
46. Spieler JF, De Pouvourville G, Amarenco P. Cost of a recurrent vs cost of first-ever stroke over an 18-month period. Eur J Neurol 2003;10:621-624.
47. Chang KC, Tseng MC, Weng HH et al. Prediction of length of stay of first-ever ischemic stroke. Stroke 2002;33:2670-2674.
48. Levy E, Gabriel S, Dinet J. The comparative medical costs of atherothrombotic disease in European countries. Pharmacoeconomics 2003;21:651-659.
49. Hass SL, Ransom JE, Brown RD Jr et al. The impact of stroke on the cost and level of care in nursing homes: a retrospective population-based study. Mayo Clin Proc 2001;76:493-500.
50. van Bergen PF, Jonker JJ, van Hout BA et al. Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. JAMA 1995;273:925-928.
51. Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin Thromb Hemost 1999;25:103-107.
52. Lafata JE, Martin SA, Kaatz S et al. The cost-effectiveness of different management strategies for patients on chronic warfarin therapy. J Gen Intern Med 2000;15:31-37.
53. Ansell JE, Hughes R. Evolving models of warfarin management: anticoagulation clinics, patient self-monitoring, and patient self-management. Am Heart J 1996;132:1095-1100.
54. Breukink-Engbers WG. Monitoring therapy with anticoagulants in The Netherlands. Semin Thromb Hemost 1999;25:37-42.
55. Sudlow CM, Rodgers H, Kenny RA et al. Service provision and use of anticoagulants in atrial fibrillation. BMJ 1995;311:558-560.
56. Parry D, Fitzmaurice D, Raftery J. Anticoagulation management in primary care: a trial-based economic evaluation. Br J Haematol 2000;111:530-533.
57. Parry D, Bryan S, Gee K et al. Patient costs in anticoagulation management: a comparison of primary and secondary care. Br J Gen Pract 2001;51:972-976.
58. Lafata JE, Martin SA, Kaatz S et al. Anticoagulation clinics and patient self-testing for patients on chronic warfarin therapy: a cost-effectiveness analysis. J Thromb Thrombolysis 2000; 9(Suppl. 1):S13-S19.
59. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working Group for the Study of Patient Self-Management of Oral Anticoagulation. JAMA 1999;281:145-150.
60. Fitzmaurice DA, Murray ET, Gee KM et al. A randomised controlled trial of patient self management of oral anticoagulation treatment compared with primary care management. J Clin Pathol 2002;55:845-849.
61. Gorter JW, Oostenbrink JB, Tangelder MJ. Costs of outpatient anticoagulant treatment in patients with cerebral and peripheral arterial occlusive disease. Thromb Haemost 2001;85:52-56.
62. Davies A, Buxton MJ, Patterson DL et al. Anti-coagulant monitoring service delivery: a comparison of costs of hospital and community outreach clinics. Clin Lab Haematol 2000;22:33-40.
63. Fitzmaurice DA, Hobbs FD, Murray ET. Primary care anticoagulant clinic management using computerized decision support and near patient International Normalized Ratio (INR) testing: routine data from a practice nurse-led clinic. Fam Pract 1998;15:144-146.
64. Taylor FC, Gray A, Cohen H et al. Costs and effectiveness of a nurse specialist anticoagulant service. J Clin Pathol 1997;50:823-828.
65. Fitzmaurice DA, Machin SJ, British Society of Haematology Task Force for Haemostasis and Thrombosis. Recommendations for patients undertaking self management of oral anticoagulation. BMJ 2001;323:985-989.
66. Hennessy BJ, Vyas M, Duncan B et al. Evaluation of an alternative model of anticoagulant care. Ir J Med Sci 2000;169:34-36.
67. Fitzmaurice DA, Hobbs FD, Murray ET et al. Evaluation of computerized decision support for oral anticoagulation management based in primary care. Br J Gen Pract 1996;46:533-535.
68. Gage BF, Fihn SD, White RH. Management and dosing of warfarin therapy. Am J Med 2000;109:481-488.
69. Ansell JE, Buttaro ML, Thomas OV et al. Consensus guidelines for coordinated outpatient oral anticoagulation therapy management. Ann Pharmacother 1997;31:604-615.
70. Palareti G, Leali N, Coccheri S et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996;348:423-428.
71. Bond S, Rhodes S, James R et al. Health care costs of treating bleeding and other complications associated with warfarin treatment of atrial fibrillation and venous thromboembolism in the UK. Br J Haematol 2004;125(Suppl. 1):58.
72. Terént A, Marké LA, Asplund K et al. Costs of stroke in Sweden: a national perspective. Stroke 1994;25:2363-2369.
73. Levine MN, Raskob G, Beyth RJ et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(Suppl. 3):287S-310S.
74. Tengs TO, Yu M, Luistro E. Health-related quality of life after stroke a comprehensive review. Stroke 2001;32:964-972.
75. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med 2002;162:541-550.
76. Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323:1218-1222.
77. Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999;318:1324-1327.
78. Man-Son-Hing M, Laupacis A, O'Connor A et al. Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med 1996; 156:1841-1848.
79. Lancaster TR, Singer DE, Sheehan MA et al. The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. Arch Intern Med 1991;151:1944-1949.
80. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-1836.
81. Devereaux PJ, Anderson DR, Gardner MJ et al. Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. BMJ 2001; 323:1218-1222.
82. Wang TJ, Massaro JM, Levy D et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. JAMA 2003;290: 1049-1056.
83. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457.
84. Segal JB, McNamara RL, Miller MR et al. Prevention of thromboembolism in atrial fibrillation. A meta-analysis of trials of anticoagulants and antiplatelet drugs. J Gen Intern Med 2000;15:56-67.
85. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation (SPAF) Study: final results. Circulation 1991;84:527-539.
86. van Walraven C, Hart RG, Wells GA et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:936-943.
87. Wolf PA. An overview of the epidemiology of stroke. Stroke 1990;21(Suppl. 9):II4-II6.
88. Lumley T, Kronmal RA, Cushman M et al. A stroke prediction score in the elderly: validation and Web-based application. J Clin Epidemiol 2002;55:129-136.
89. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285: 2864-2870.
90. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
91. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000;9: 283-292.
92. Hylek EM, Go AS, Chang Y et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349:1019-1026.
93. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
94. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med 1994;154:1945-1953.
95. Kalra L, Yu G, Perez I et al. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ 2000; 320:1236-1239.
96. Hasenkam JM, Knudsen L, Kimose HH et al. Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation. Thromb Res 1997;85:77-82.
97. Samsa GP, Matchar DB, Goldstein LB et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med 2000;160:967-973.
98. Gurwitz JH, Monette J, Rochon PA et al. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting. Arch Intern Med 1997;157:978-984.
99. Yermiahu T, Arbelle JE, Shwartz D et al. Quality assessment of oral anticoagulant treatment in the Beer-Sheba district. Int J Qual Health Care 2001;13:209-213.
100. Matchar DB, Samsa GP, Cohen SJ et al. Improving the quality of anticoagulation of patients with atrial fibrillation in managed care organizations: results of the managing anticoagulation services trial. Am J Med 2002;113:42-51.
101. Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med 1998;158:1641-1647.
102. Foss MT, Schoch PH, Sintek CD. Efficient operation of a high-volume anticoagulation clinic. Am J Health Syst Pharm 1999;56:443-449.
103. Samsa GP, Matchar DB, Phillips DL et al. Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making. J Thramb Thrombolysis 2002;14:103-111.
104. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000;9:283-292.
105. Ansell JE, Patel N, Ostrovsky D et al. Long-term patient self-management of oral anticoagulation. Arch Intern Med 1995; 155:2185-2199.
106. Wilson SJ, Wells PS, Kovacs MJ et al. Comparing the quality of oral anticoagulant management by anticoagulation clinics and by family physicians: a randomized controlled trial. CMAJ 2003;169:293-298.
107. Sidhu P, O'Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann Thorac Surg 2001;72:1523-1527.
108. Beyth RJ, Quinn L, Landefeld CS. A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. Ann Intern Med 2000; 133:687-695.
109. Hollowell J. Is warfarin still underused in patients with atrial fibrillation? A literature review. (Abstract 5) Cerebrovasc Dis 2004;17(Suppl. 5):125.
110. Frykman V, Beerman B, Ryden L et al; Medical Products Agency Swedish Society of Cardiology. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 2001;22:1954-1959.
111. Bushnell CD, Matchar DB. Pharmacoeconomics of atrial fibrillation and stroke prevention. Am J Manag Care 2004;10(Suppl. 3):S66-S71.